FDA Clears Kringle Pharma's US Trial of Oremepermin Alfa for Acute Spinal Cord Injury

MT Newswires Live10-19

Kringle Pharma (TYO:4884) said the U.S. FDA has cleared its Investigational New Drug application for oremepermin alfa, a recombinant human hepatocyte growth factor, to treat acute spinal cord injury.

The clearance enables Kringle to advance preparations for a U.S. Phase 3 trial and marks a key milestone in its global development strategy, according to a Tokyo bourse filing on Monday.

Kringle has completed Phase 1/2 and Phase 3 trials in Japan generating safety and efficacy evidence, and is conducting an additional Japanese Phase 3 trial ahead of a future regulatory submission.

It has also secured Orphan Drug Designation for acute SCI in Japan, the U.S. and Europe.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment